Republic of Korea-based Celltrion Healthcare launched its high-concentration adalimumab biosimilar in Canada and won several Brazilian tenders to supply its infliximab biosimilar.
Celltrion Healthcare, based in the Republic of Korea, has made a couple advances in its biosimilar business endeavors, launching its adalimumab biosimilar (Yuflyma) on the Canadian market and winning exclusive marketing rights in several areas of Brazil.
Canadian Launch of Yuflyma
Celltrion launched its high-concentration, citrate-free formulation (100 mg /ml) of its biosimilar referencing Humira across Canada. Yuflyma is available in an auto-injector pen and in a prefilled syringe.
Yuflyma received regulatory approval from Health Canada in December 2021 for 10 indications including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohns disease, adult ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uveitis, and pediatric uveitis.
“With the specific features of Yuflyma, such as lower volume of injection and a high-concentration formulation without citrate, it may provide additional clinical benefits for patients," said John K. Marshall, MD, professor of medicine and director of the division of gastroenterology at McMaster University, in Celltrion’s statement.
Celltrion also launched Celltrion Connect, a patient-focused support program intended to provide guidance with reimbursement navigation, financial assistant, injection and nurse support services, and pharmacy support services for patients and health care providers in Canada.
Tender Wins in Brazil
Celltrion also announced that it had won a tender offer presented by the Brazilian Federal Government for the purchase of Remsima, an infliximab biosimilar referencing Remicade.
The company won 12 state bids in Brazil to supply the biosimilar, including the bid for São Paulo, the largest state bid available in the country.
Tenders systems are designed to encourage competition among companies for the chance to win a contract, also known as a tender, for exclusive or near-exclusive rights to supply a biologic or biosimilar to a geographic area or health care setting. Companies submit pricing bids to the tender organizers and a contract is awarded to the lowest-cost product or products, depending on whether the system allows for multiple winners. Several European markets, including France and the United Kingdom, have adopted tender systems.
The tender offer would allow for Remsima to be supplied to patients through the federal and state governments, allowing about 2 thirds of the total Brazilian population requiring treatment with infliximab products to have access to the biosimilar.
Infliximab products are used to treat several rheumatic conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohns disease, plaque psoriasis, and ulcerative colitis.
“The winning of the bid is an important milestone to broaden patient access to effective and affordable biosimilar medicines in countries like Brazil and Mexico, which are 2 of the biggest pharmaceutical markets in Latin America,” said HoUng Kim, PhD, head of the Medical and Darketing Division at Celltrion, in a company statement.
Additionally, Celltrion has obtained exclusive marketing rights for Remsima in Peru, Chile, Costa Rica for the previous 3 to 4 years as a result of winning tender bids in those countries.
Remsima is the third biosimilar developed by Celltrion to win a tender for Brazil’s market. In 2021, Celltrion signed an agreement with the Brazilian Ministry of Health to supply Herzuma, the company’s trastuzumab biosimilar referencing Herceptin, and Truxima, its rituximab biosimilar referencing Rituxan, to the Brazilian market. Celltrion also won a tender offer by the Institute of Health for the Welfare of the United Mexican States for Truxima for 1 year.
To further establish the companies in Latin America, Celltrion establishing an entity in Brazil and Mexico to manage sales and marketing activities for its biosimilars in the region.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.